Biopharma | January 11, 2026
Prokaryotics and Basilea team up to tackle deadly fungal infections
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
The state-of-the-art laboratory opens at the Corewell Health Southfield Center in early 2027
Subscribe To Our Newsletter & Stay Updated
